UK Strikes Deals For 90M More Covid Vax Doses NK#143692

Cornelia Mascio
Agosto 15, 2020

Novavax also plans to manufacture some of the vaccine using FUJIFILM Diosynth Biotechnologies's facilities in Billingham, Stockton-on-Tees. Phase 1 data from the Company's Phase 1/2 randomized, observer-blinded, placebo-controlled trial shows that NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The Commission now has agreed the basis for a contractual framework for the purchase of 300 million doses of the AstraZeneca vaccine, with an option to purchase 100 million more, on behalf of EU Member States.

According to the World Health Organization, almost 3.7 million cases of COVID-19 have been recorded in Europe since the start of the pandemic, and 218,383 deaths.

Reuters reported that J&J is also working with the United Kingdom government on a phase 3 trial testing a two-dose regimen of its vaccine candidate, running in parallel to a phase 3 trial of its single-dose vaccine.

Pharmaceuticals and biologics player Biological E Limited (BE) on Thursday said it has entered into an agreement with Janssen Pharmaceutica NV (Janssen), which is part of Johnson & Johnson (J&J), for manufacturing J&J's Covid-19 vaccine candidate, Ad26.COV2.S.

Biological E. Ltd in an email also said it has signed a licensing agreement with Houston-based Baylor College of Medicine to develop a COVID-19 vaccine.

The World Health Organisation (WHO) has declared COVID-19, caused by the novel coronavirus SARS-CoV-2, a pandemic. "While we are doing everything we can to ensure the British people get access to a successful vaccine as soon as possible, nobody is safe until we are all safe so global cooperation is absolutely critical if we are to defeat this virus once and for all", he said.

No vaccine has yet proven to work, but more than 20 candidates are in clinical trials.

Novavax will also conduct a phase 3 clinical trial of its vaccine candidate with support from the UK's National Institute for Health Research (NIHR), and has partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK.

The trial will assess the ability of NVX-CoV2373 to protect against symptomatic Covid-19 disease as well as evaluate antibody and T-cell responses.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE